PR Newswire: news distribution, targeting and monitoring
2014

Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014

Share with Twitter Share with LinkedIn

LONDON, February 4, 2014 /PRNewswire/ --

Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 - 22 in Copenhagen, Denmark.

As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme. With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study strongly demonstrated ST10's potential to be the only effective oral treatment for ferrous intolerant IDA patients, in addition to being an effective alternative to intravenous iron treatment.

The abstract about ST10, entitled "Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron", will be presented during the Digital Oral Poster Session 9 - Therapy today - in Room 9, Hall B on the Ground level of the Bella Centre at 13.07 on Friday 21st February 2014.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3 programme of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:

Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Lindsey Neville
Tel +44(0)20-7920-2333
Email: shieldtherapeutics@consilium-comms.com

SOURCE Shield Therapeutics



Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release